AL001 + Placebo + Open label - AL001
Phase 3Terminated 0 views this week 0 watching💤 Quiet
Interest: 22/100
22
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Frontotemporal Dementia
Conditions
Frontotemporal Dementia
Trial Timeline
Jul 23, 2020 → Jan 6, 2026
NCT ID
NCT04374136About AL001 + Placebo + Open label - AL001
AL001 + Placebo + Open label - AL001 is a phase 3 stage product being developed by Alector for Frontotemporal Dementia. The current trial status is terminated. This product is registered under clinical trial identifier NCT04374136. Target conditions include Frontotemporal Dementia.
What happened to similar drugs?
0 of 1 similar drugs in Frontotemporal Dementia were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
17
Activity
0
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04374136 | Phase 3 | Terminated |
Competing Products
7 competing products in Frontotemporal Dementia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AL001 | Alector | Phase 2 | 25 |
| LY3884963 + Methylprednisolone + Optional Sirolimus + Optional Prednisone | Eli Lilly | Phase 1/2 | 36 |
| galantamine hydrobromide | Johnson & Johnson | Phase 2 | 35 |
| memantine hydrochloride | Lundbeck | Phase 3 | 37 |
| Syntocinon | Brain Biotech | Phase 2 | 21 |
| DNL593 + Placebo | Denali Therapeutics | Phase 1/2 | 30 |
| PBFT02 | Passage Bio | Phase 1/2 | 29 |